Abstract Natural killer (NK)/T-cell lymphomas are aggressive malignancies with a
predilection for Asian and South American populations. Epstein–Barr virus (EBV) infection in …

Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) is a subtype of mature T-and
natural killer cell lymphomas characterized by its association with Epstein-Barr virus and …

This study aimed to assess the efficacy and safety of treatment with avelumab, an anti–
programmed death ligand 1 (PD-L1) antibody, in patients with relapsed or refractory …

Abstract This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a
humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell …

PURPOSE Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is
a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This …

Background Peripheral T-cell lymphomas (PTCLs) are uncommon and their frequency is
regionally heterogeneous. Several studies have been conducted to evaluate the clinical …

The rapidly increasing use of high-throughput screening had produced a plethora of
expanding knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL) …

Extranodal natural killer (NK)/T-cell lymphoma, nasal type, is a rare peripheral T-cell
lymphoma associated with Epstein-Barr virus. It most often presents as limited-stage disease …

We report a first-in-human clinical trial using chimeric antigen receptor (CAR) T cells
targeting CD37, an antigen highly expressed in B-and T-cell malignancies. Five patients …

Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural
killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and the …